TORONTO, Ontario and CAMBRIDGE, MA, June 27, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX:PMN.TO) (OTC-BB:ARFXF), a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that, to meet the criteria to list its common shares on the Nasdaq Capital Market (“NASDAQ”), the Board of Directors has approved a 1-for-60 reverse share split (the “Reverse Split”), of the Company's issued and outstanding common shares.
PROMIS ANNOUNCES REVERSE SHARE SPLIT TO MEET NASDAQ LISTING CRITERIA
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Cisco%20Systems%2C%20Inc_%20magnified%20logo-by%20Pavel%20Kapysh%20via%20Shutterstock.jpg)
/NVIDIA%20Corp%20logo%20on%20phone%20and%20AI%20chip-by%20Below%20the%20Sky%20via%20Shutterstock.jpg)